Registrars: | Equiniti |
Brands: | Lucozade, Horlicks, Ribena, Paxil, Seroxat |
CEO: | Emma Walmsley |
Chief Finance Officer: | Julie Brown |
Independent Non-Executive Director: | Jesse Goodman |
Independent Non-Executive Director: | Vishal Sikka |
Independent Non-Executive Director: | Elizabeth (Liz) McKee Anderson |
Independent Non-Executive Director: | Anne Beal |
Independent Non-Executive Director: | Urs Rohner |
Independent Non-Executive Director: | Harry (Hal) C. Dietz |
Non-Executive Chairman: | Jonathan Symonds |
Senior Independent Non-Executive Director: | Charles Bancroft |
Non-Executive Dir: | Wendy Becker , Jeannie Lee , Hal Barron |
Address: | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS |
Phone: | +44 (0)20 8047 5000 |
Website: | http://www.gsk.com |
Sector: | Pharma and Biotech(LSE) |
Index: | techMARK, FTSE 100, FTSE 350, FTSE All-Share |
Overseas Listings: | BATSLON:GSKL, NYSE:GSK |
ISIN: | GB00BN7SWP63 |
Currency | UK Pounds |
Share Price | 1,653.00p |
Change Today | 12.50p |
% Change | 0.76 % |
52 Week High | 1,711.20 |
52 Week Low | 1,316.00 |
Volume | 3,273,134 |
Shares Issued | 4,144.88m |
Market Cap | £68,515m |
RiskGrade | 129 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 8 |
Buy | 5 |
Neutral | 9 |
Sell | 2 |
Strong Sell | 0 |
Total | 24 |
Latest | Previous | |
---|---|---|
Q4 | Q3 | |
Ex-Div | 22-Feb-24 | 16-Nov-23 |
Paid | 11-Apr-24 | 11-Jan-24 |
Amount | 16.00p | 14.00p |
Time | Volume / Share Price |
16:35 | 1,484,603 @ 1,653.00p |
16:35 | 3,000 @ 1,653.00p |
16:35 | 3,859 @ 1,653.00p |
16:35 | 219 @ 1,653.00p |
16:35 | 454 @ 1,653.00p |
You are here: research